Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Premier Partners

Investor type Hedge Fund

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 22
Rounds per year 1.47
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Key employees Soon
Stages of investment
Private Equity

Areas of investment

  • Therapeutics
  • Biotechnology
  • Artificial Intelligence
  • Health Care
  • Apps
Summary

Premier Partners is the famous Corporate Investor, which was founded in 2005. The fund was located in Asia if to be more exact in South Korea. The main department of described Corporate Investor is located in the Seoul.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this Corporate Investor is 5 percentage points less often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The top activity for fund was in 2019.

The typical case for the fund is to invest in rounds with 5 participants. Despite the Premier Partners, startups are often financed by Daesung Private Equity, ARCH Venture Partners, WONIK Investment Partners. The meaningful sponsors for the fund in investment in the same round are POSCO Venture Capital, DSC Investment, Korea Kolmar Co.. In the next rounds fund is usually obtained by Shinhan Bank, ST Telemedia, LB Investment.

Among the most popular fund investment industries, there are Biotechnology, Software. For fund there is a match between the country of its foundation and the country of its the most frequent investments - South Korea. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Socar, BlackThorn Therapeutics, Bespin Global Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

Read more

Funds with similar focus

Funds from South Korea
Funds with similar focus located in South Korea:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ARCH Healthcare Fund -
Atlantic Quantum Malaysia, Petaling Jaya, Selangor
Beyond Black Berlin, Berlin, Germany
CG Health Ventures Barcelona, Catalonia, Spain
Deerfield Management New York, New York, United States
Devenish Nutrition Fairmont, Minnesota, United States
Dunamis Ventures Central, Central Region, Singapore
ENGIE New Ventures France, Ile-de-France, Paris
Fifth Third Capital Cincinnati, Ohio, United States
Hengqin Xiaozhong Youxuan Guquan Touzi China, Guangdong, Zhuhai
HP Ventures Group Chicago, Illinois, United States
MCube8 -
Moffu Labs -
Morgan Keegan & Company Memphis, Tennessee, United States
NIH Surgery -
Plastic Omnium -
Venture Catalysts Matosinhos, Porto, Portugal
WATTAGE FINANCE-OH, LLC -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Xangle

Angel Investment
Finance
$17M09 May 2022 Seocho, Seoul-t'ukpyolsi, South Korea

KaliVir Immunotherapeutics

Health Care
Pharmaceutical
Therapeutics
16 Mar 2022 Pittsburgh, Pennsylvania, United States

Zikooin Company

Food Processing
$17M23 Nov 2021 South Korea, Gyeonggi-do, South Korea

Upstage AI

Artificial Intelligence
Communications Infrastructure
$27M03 Sep 2021 Yongin, Ch'ungch'ong-namdo, South Korea

Aardvark Therapeutics

Health Care
Therapeutics
$29M05 Aug 2021 San Diego, California, United States

Iksuda Therapeutics

Biopharma
Biotechnology
Therapeutics
$47M07 Jun 2021 Newcastle upon Tyne, England, United Kingdom

Artificial Intelligence
Computer Vision
Machine Learning
Natural Language Processing
SaaS
$9M02 Feb 2021 California, United States

Supergene

Casual Games
Internet
$19M01 Dec 2019 Pangyo, Kyonggi-do, South Korea

Aardvark Therapeutics

Health Care
Therapeutics
$15M29 Nov 2019 San Diego, California, United States
News
Aardvark Therapeutics Closes $29M Series B Funding

– Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
– The company completed a $29m Series B financing.
– The round was led by Sorrento Therapeutics with participation from existing investors including Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega.
– The funds raised will be deployed to advance the company’s pipeline of programs for metabolic diseases.

Iksuda Therapeutics Closes $47 Million Financing Round

– Iksuda Therapeutics (Iksuda) has completed a US $47m financing round.
– The round was co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners.
– Iksuda’s lead pre-clinical candidate, IKS03, is a best-in-class CD19-targeted ADC candidate for B-cell cancers.
– The investment will enable progression of IKS03 to first-in-human phase 1 clinical trials.
– It will also be used to accelerate the Company’s earlier-stage programmes including IKS04 and IKS012 to IND filing.
– Iksuda’s ADC programmes target tumours that currently have limited treatment options and high relapse rates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Premier Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: